7:21 AM ET
8-K/A
M&A Deal
Processa Pharmaceuticals M&A Deal with Vidya Therapeutics, Inc.
Processa Pharmaceuticals filed an amendment to its 8-K to provide audited financial statements and pro forma information following its acquisition of Vidya Therapeutics. The deal adds VT7208, a CNS-penetrant BTK inhibitor, to Processa's pipeline for the treatment of autoimmune conditions like multiple sclerosis and food allergies.
- Counterparty
- Vidya Therapeutics, Inc.